Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003341 · ClinicalTrials.gov registry record · Phase 3
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
A Phase 3 study of Lymphoma and Leukemia, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 275
- Enrollment target
- 18
- Study locations
NCT00003341 is a Phase 3 study of Lymphoma and Leukemia that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 275 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (43% lower). The trial reports 18 study locations across 12 states.
The verdict
NCT00003341, a Phase 3 study of Lymphoma and Leukemia, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 275 participants
- Enrollment target
- 18
- Study locations
Study Summary
RATIONALE: Drugs such as epoetin alfa may relieve anemia caused by chemotherapy. The best time for giving epoetin alfa during chemotherapy is not yet known. PURPOSE: Randomized phase III trial to study the effectiveness of epoetin alfa in treating anemia in patients with lymphoma, chronic lymphocytic leukemia, or multiple myeloma who are receiving chemotherapy.
Conditions Studied
Interventions
- PROCEDURE quality-of-life assessment
- BIOLOGICAL epoetin alfa
Study Locations (18)
California
- Alta Bates Comprehensive Cancer Center - Berkeley
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
- Comprehensive Cancer Centers of the Desert - Palm Springs
- Division of Oncology - Palo Alto
Illinois
- Rush Cancer Institute - Chicago
- University of Chicago Cancer Research Center - Chicago
New York
- Roswell Park Cancer Institute - Buffalo
- Memorial Sloan-Kettering Cancer Center - New York
District of Columbia
- George Washington University Medical Center - Washington D.C.
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Maryland
- Marlene & Stewart Greenebaum Cancer Center, University of Maryland - Baltimore
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
North Carolina
- Duke Comprehensive Cancer Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 275 participants |
| Start Date | 1997-12 |
| Est. Completion | 2003-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003341
The ClinicalTrials.gov registry entry for NCT00003341 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 275 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (43% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which quality-of-life assessment is the first listed.
NCT00003341 reports 18 study locations spanning 12 distinct geographic areas - top geographies include California, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT00003341 about?
NCT00003341 is a clinical study titled "Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy". RATIONALE: Drugs such as epoetin alfa may relieve anemia caused by chemotherapy. The best time for giving epoetin alfa during chemotherapy is not yet known. PURPOSE: Randomized phase III trial to study the effectiveness of epoetin alfa in treating anemia in patients with lymphoma, chronic lymphocyt...
What is the current status of trial NCT00003341?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 275 participants. The study started on 1997-12. Estimated completion is 2003-09.
What conditions does trial NCT00003341 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia, Anemia, Multiple Myeloma and Plasma Cell Neoplasm.
What interventions are being tested in trial NCT00003341?
The interventions under investigation include: quality-of-life assessment (PROCEDURE), epoetin alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003341?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003341 being conducted?
This trial has 18 study locations across California, District of Columbia, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
RECRUITING · Phase 3
-
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
RECRUITING · Phase 3
-
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
RECRUITING · Phase 3
-
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
ACTIVE NOT RECRUITING · Phase 3
-
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 3
-
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.